Hyperinflammatory Syndromes After Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Messenger RNA vaccination in Individuals With Underlying Immune Dysregulation

Joseph M Rocco; Christina Mallarino-Haeger; Attiya H Randolph; Susan M Ray; Marcos C Schechter; Christa S Zerbe; Steven M Holland; Irini Sereti

doi:10.1093/cid/ciab1024

Hyperinflammatory Syndromes After Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Messenger RNA vaccination in Individuals With Underlying Immune Dysregulation

Clin Infect Dis. 2022 Aug 24;75(1):e912-e915. doi: 10.1093/cid/ciab1024.

Authors

Joseph M Rocco¹, Christina Mallarino-Haeger², Attiya H Randolph³, Susan M Ray², Marcos C Schechter², Christa S Zerbe¹, Steven M Holland¹, Irini Sereti¹

Affiliations

¹ National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA.
² Department of Medicine, Emory University School of Medicine, Atlanta, Georgia, USA.
³ Department of Medicine, George Washington University of Medicine and Health Sciences, Washington, DC, USA.

Abstract

The development of effective severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) messenger RNA (mRNA) vaccines has been a significant accomplishment. Adverse events are extremely rare, but continued surveillance is important, especially in at-risk populations. In 5 patients with preexisting immune dysregulation, hyperinflammatory syndromes, including hemophagocytic lymphohistiocytosis, developed after SARS-CoV-2 mRNA vaccination. Early recognition of this rare condition is essential.

Keywords: COVID-19; Inflammation; Vaccination; hemophagocytic lymphohistiocytosis.

Published by Oxford University Press for the Infectious Diseases Society of America 2021.

Publication types

Research Support, N.I.H., Intramural

MeSH terms

COVID-19* / prevention & control
Humans
Middle East Respiratory Syndrome Coronavirus*
RNA, Messenger / genetics
SARS-CoV-2 / genetics
Vaccination / adverse effects

Substances

RNA, Messenger